Brief: Ocumension Therapeutics Initiation Of Second Phase 3 Clinical Trial Of OT-301 In U.S.

Nicox SA

11/11/2020 12:01

Nov 11 (Reuters) - Ocumension Therapeutics  1477.HK :
    * SECOND PHASE III CLINICAL TRIAL OF OT-301(NCX 470)
INITIATED IN
U.S. BY GROUP'S LICENSING PARTNER, NICOX S.A.

Source text https://bit.ly/36netOR
Further company coverage:  1477.HK 

 ((Reuters.Briefs@thomsonreuters.com;))